The surgical management of medullary thyroid cancer.
Medullary thyroid cancer (MTC), accounts for approximately 5% to 10% of all thyroid cancers. Significant advances in the understanding of the biology and clinical outcomes of MTC have been made over the last decade, culminating most recently in the publication of treatment guidelines by the American Thyroid Association that follow an evidence-based approach that is summarized in this presentation. Prognosis, genetic testing, surgical technique, and re-operation are also discussed.
Dackiw
Alan P B
AP
Division of Endocrine and Oncologic Surgery, Department of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. adackiw1@jhmi.edu
D018276:Carcinoma, Medullary / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D004252:DNA Mutational Analysis; D019317:Evidence-Based Medicine; D006801:Humans; D010535:Laparoscopy; D009377:Multiple Endocrine Neoplasia / Q000235:genetics / Q000473:pathology / Q000601:surgery; D037981:Neck Dissection / Q000379:methods; D017410:Practice Guidelines as Topic; D011379:Prognosis; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics; D012086:Reoperation / Q000379:methods; D013964:Thyroid Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D013965:Thyroidectomy / Q000379:methods*
D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human